To study new cancer substitutive therapies of cancer targeted at protein moesin

In an online article published in Journal of Clinical Research at the University of South Carolina Medical University (MUSC) on March 13, 2017, the researchers reported preclinical studies showing that the membrane domain of tissue protein moesin controls the function of regulatory T cells (Treg) and the abundance and stability of transforming growth factor-β (TGF-β) receptors on the cell surface, providing potential therapeutic targets for cancer immunotherapy. Even so, more research involving recombinant human proteins should be conducted.

Their results show that TGF- β acts at the protein level to produce Treg in the tumor microenvironment. Although the human immune system is capable of eradicating cancer, Treg inhibits immune responses and protects cancer cells from tumor cytotoxicity (i.e., cytotoxic) and T cells effect.

When T cells, leukocyte subtypes, effectively attack and kill tumor cells, the protein TGF- β is activated. However, the immune system has a complex check and balance network to ensure that the body does not produce so much toxic T cells that it hurts its own cells and tissues. Inhibition of moesin can help to prevent natural T cells from converting to Treg, thereby restoring an antitumor immune response.

"Because moesin supports more Treg production, we can design moesin inhibitors to stop or slow the activity of TGF-β signaling and slow down Treg transformation so that antitumor T cells can have the opportunity to see cancer and eradicate it," said Zihai Li, a senior author of this article, MUSC microbes Director of the Department of Immunology and Immunology.

Perhaps the most notable outcome is the study of melanoma mouse models involving the treatment of adoptive T cells. In adoptive T cell therapy, tumor killer T cells are harvested from people or animals suffering from cancer and amplified or otherwise "sensitized" before being reintroduced into the donor. Although these regressive cells can kill tumors very effectively, they do not always survive for long periods of time.

The MUSC team showed that these re-cultured anti-cancer CD8 + T cells were not only activated and expanded rapidly in mice lacking moesin, but they also survived for a longer period of time and reduced the likelihood of recurrence. In fact, after the transfer of adoptive T cells, all mice with moesin were recurrent, and most mice lacking moesin were cured.

These findings suggest that moesin may be the development of new therapeutic targets for the treatment of cancer and Treg-related immune diseases. Moesin's chemotherapeutic agents can control the function of T cells by inhibiting moesin in cancer or inducing its treatment of autoimmune diseases. Moesin modulators can also be combined with current immunotherapy regimens. These findings are of great significance to the field and provide many directions for further research on alternative therapies. Flarebio offers recombinant proteins of good quality such as recombinant CDH15 at competitive prices.